Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial

Using patient-reported outcomes data from the phase 3 GOYA trial of CHOP plus obinutuzumab or rituximab in patients with CD20-positive DLBCL, researchers found that, from the study baseline to cycle 3 day 1, every 1-point increase in fever symptoms was associated with a 41% higher risk of death (HR, 1.41; p = 0.01). Further, every 1-point increase in lumps or swelling symptoms was associated with a 27% higher risk of disease progression or death (PFS events; HR, 1.27; p = 0.01) and a 29% higher risk of death (OS events; HR, 1.29; p = 0.02).